Compare ADMA Biologics Inc (ADMA) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Consolidated Edison, Inc. — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Consolidated Edison, Inc. trades at $112.79 (market cap $41.64B). The key difference: Consolidated Edison, Inc. is far larger — about 19.5× ADMA Biologics Inc's market cap, and Consolidated Edison, Inc. pays a 3.08% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ED | |
|---|---|---|
Market Cap | $2.13B | $41.64B |
Sector | Health | Utilities |
52-Week High | $20.38 | $115.46 |
52-Week Low | $7.60 | $95.37 |
Enterprise Value | $2.20B | $68.67B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Consolidated Edison (ED) trades at $112.99, down 0.88% on the day, with a bullish technical signal from moving averages. The utility company reported mixed Q1 2026 earnings but maintains steady revenue growth and a 12.52% net income margin. Recent news highlights grid upgrades and a new $2 billion equity offering program announced May 8, 2026.
ED offers stable dividend income with a 52-year growth streak but faces analyst caution with 63% hold ratings. Upside potential exists from infrastructure investments, while risks include debt levels and regulatory pressures. The consensus price target of $103.50 suggests limited near-term appreciation from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
